ORIGIN is the IBD cohort within INTEGRATE, which also includes ankylosing spondylitis and healthy participants. This framework supports investigation of shared and disease-specific oral–gut signatures.
Following IBD. Connecting biology with clinical outcomes.
A nationwide, prospective, multicentre IBD cohort
ORIGIN investigates how the oral and gut microbiome, metabolome, diet and lifestyle relate to inflammatory bowel disease. It brings together people with Crohn’s disease and ulcerative colitis across different stages of disease and treatment, alongside unaffected first-degree relatives.
Longitudinal follow-up and serial biospecimen collection support studies of disease progression, complications and response to biologic and small-molecule therapies. Clinical phenotypes are linked with microbial and metabolic profiles to identify candidate diagnostic, prognostic and treatment-response biomarkers for subsequent validation.
As the core IBD cohort within INTEGRATE, ORIGIN contributes clinically integrated data from an East Asian population. Healthy participants recruited through INTEGRATE provide a complementary reference population using standardized clinical-data and biospecimen-collection procedures.
What does ORIGIN stand for?
Omics-driven Research on the Gut-Oral Microbiome, Metabolome, Lifestyle, and Clinical Integration in Korean Inflammatory Bowel Disease.
Complementary populations for studying early disease, established phenotypes, treatment response and familial influences.
Participant stratum
Definition & research context
Inception cohort
Patients enrolled within 6 months of diagnosis and followed longitudinally from diagnosis to investigate early disease and subsequent outcomes.
Established IBD cohort
Patients with a well-characterized prior clinical course and disease phenotype, supporting investigation of disease heterogeneity and progression.
Advanced-therapy cohort
Patients enrolled when initiating a biologic or small-molecule therapy, with longitudinal follow-up of treatment response and subsequent outcomes.
Familial IBD cohort
Families with at least two affected first-degree relatives, supporting investigation of familial disease patterns.
Unaffected first-degree relatives
First-degree relatives without IBD, enrolled as family-based controls to help examine genetic and shared environmental influences.
Research approach
Clinical phenotypes, linked across biological layers.
Paired biospecimens and harmonized clinical information connect microbial communities with local and systemic metabolic features.
01 / Biospecimens & clinical data
Following change over time
Saliva, stool and blood samples, with tissue collected in selected participants, are linked to clinical phenotypes, laboratory measurements, medication exposure, disease activity, diet and lifestyle. Serial collections enable longitudinal questions about disease course and treatment.
02 / Microbial & metabolic profiling
Connecting the oral and gut ecosystems
Full-length 16S rRNA gene sequencing and shotgun metagenomics characterize oral and intestinal communities. Metabolomic profiling of saliva, stool and plasma examines their relationship with microbial variation and clinical phenotypes.
03 / Extended analyses & validation
From biological signals to testable markers
Designated subsets support virome, host genomic, transcriptomic, immunological and culturomics analyses. Integrated analyses and machine learning seek candidate biomarkers for independent validation across cohorts and populations.
Analysis platforms, sample availability and follow-up depth vary by participant stratum and designated study subset.
Publications and accepted manuscripts from ORIGIN and its investigators, listed together in reverse chronological order.
This list includes studies using ORIGIN data, earlier studies using independent cohorts, and investigator-led reviews. Each summary describes the relevant study population and scope.
A nationwide prospective observational programme investigating the oral–gut axis in immune-mediated inflammatory diseases.
INTEGRATE connects clinical information with standardized biospecimen collection and multiomics analysis in inflammatory bowel disease (IBD), ankylosing spondylitis (AS) and healthy participants. The design supports comparisons of shared and disease-specific microbial and metabolic features.
ORIGIN is the IBD-focused cohort within this wider framework. Its disease-course and treatment-response studies complement INTEGRATE’s cross-disease and healthy-reference comparisons.
IBD
ORIGIN cohort
Crohn’s disease and ulcerative colitis across five predefined participant strata, including unaffected first-degree relatives.
A complementary IMID population for investigating common and disease-specific oral–gut biological features.
Healthy reference
Healthy participants
Screened healthy individuals recruited using standardized clinical-data and biospecimen procedures.
A common platform for complementary questions
Saliva, stool and blood-derived samples connect oral and intestinal microbial communities with local and systemic metabolic features. Selected subsets support additional host and microbial analyses. ORIGIN supplies longitudinal IBD phenotypes, while the wider programme enables comparisons across diseases and with health.
The protocol describes the prospective design, participant groups, standardized sampling and integrated oral–gut microbiome and multiomics research strategy.
Principal Investigator, ORIGIN IBD Cohort Professor of Medicine, Kyung Hee University College of Medicine Director, IBD Center, Kyung Hee University Hospital
Professor Chang Kyun Lee is a gastroenterologist and physician-scientist specializing in inflammatory bowel disease. His clinical and research work connects the care of patients with Crohn’s disease and ulcerative colitis with studies of the gut and oral microbiome, metabolomics and nutrition.
He leads the ORIGIN IBD cohort and the hospital-based gut microbiome research project at Kyung Hee University Hospital. His research focuses on clinically characterized cohorts, integrated multiomics and the development and validation of candidate biomarkers for diagnosis, disease course and treatment response.
Through ORIGIN and the wider INTEGRATE framework, he welcomes academic and industry collaborations that connect biological discovery with meaningful clinical questions.
PubMed-indexed publications attributed to Chang Kyun Lee.
Compiled from PubMed on November 15, 2026, using name variants, author identifiers and affiliation checks. This is a curated snapshot; newly indexed articles may appear later.